GM-CSF and pregnancy: Evidence of significantly reduced blood concentrations in unexplained recurrent abortion efficiently reverted by intravenous immunoglobulin treatment

American Journal of Reproductive Immunology

Volumn 50, Issue 3, 2003, Pages 232-237

  Perricone, Roberto ^a   De Carolis, Caterina ^b   Giacomelli, Roberto ^c   Guarino, Maria D ^a   De Sanctis, Giuliana ^a   Fontana, Luigi ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b ASL RMC   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

IVIg therapy; Pregnancy failure; Th 2 cytokines

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN;

ARTICLE; BODY WEIGHT; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; DRUG INFUSION; ENZYME IMMUNOASSAY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PERIPHERAL CIRCULATION; PREGNANCY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECURRENT ABORTION; SPONTANEOUS ABORTION;

ABORTION, HABITUAL; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; PREGNANCY; PREGNANCY OUTCOME;

EID: 0041425213     PISSN: 87558920     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0897.2003.00083.x     Document Type: Article

References (30)

1. Wegmann T, Lin H, Gulbert L, Mosmann T: Bidirectional cytokine interactions in maternal-fetal relationship: Is successful pregnancy a Th2 phenomenon? Immunol Today 1993; 14:353-356.
2. Kruse N, Greif M, Moriabadi NF, Marx L, Toyka Kv, Rieckmann P: Variations in cytokine mRNA expression during normal human pregnancy. Clin Exp Immunol 2000; 119:317-322.
3. Kelemen K, Paldi A, Tinneberg H, Torok A, Szekeres-Bartho J: Early recognition of pregnancy by the maternal immune system. Am J Reprod Immunol 1998; 39:351-355.
4. Romagnani S: The Th1/Th2 paradigm. Immunol Today 1997; 18:263-266
5. Clark DA, Chaouat G: What do we know about spontaneous abortion mechanisms? Am J Reprod Immunol 1989; 19:28-37.
6. Robertson SA, Seamark R, Guilbert LJ, Wegmann TG: The role of cytokines in gestation. Crit Rev Immunol 1994; 14:239-292.
7. Chaouat G, Menu E, Clark DA, Dy M, Minkowski M, Wegmann TG: Control of fetal survival in CBA × DBA/2 mice by lymphokine therapy. J Reprod Fertil 1990; 89:447-458.
8. Pasetto N, Piccione E, Zicarci A, Fontana L, De Carolis C, Perricone R, Pontieri G, Ticconi C: Cytokine production by human fetal membranes and uterine decidua at term gestation in relation to labour. Placenta 1993; 14:361-364.
9. Coulam CB, Stephenson M, Stern JJ, Clark DA: Immunotherapy or recurrent pregnancy loss: Analysis of results from clinical trials. Am J Reprod Immunol 1996; 35:352-359.
10. De Carolis C, Vaquero E, Miriello D, Ruggiero G, Valensise H, Perricone R, Fontana L, Romanini C: Successful high dose intravenous immunoglobulins treatment in recurrent autoimmune or alloimmune spontaneous abortion. Int J Immunopathol Pharmacol 1997; 10:125-131.
11. Stephenson MD, Dreher K, Houlihan E, Wu V: Prevention of unexplained recurrent spontaneous abortion using intravenous immunoglobulin: A prospective, randomized, double-blinded, placebo-controlled trial. Am J Reprod Immunol 1998; 39:82-88.
12. Carp HJ, Toder V, Gazit E, Ahiron R, Torchinski A, Mashlach S, Shoenfeld Y: Further experience with intravenous immunoglobulin in women with recurrent miscarriage and poor prognosis. Am J Reprod Immunol 2001; 46:268-273.
13. Kazatchine MD, Kaveri SV: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345:747-755.
14. Mollnes TE, Hogasen K, De Carolis C, Vaquero E, Nielsen EW, Fontana L, Perricone R: High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol 1998; 48:312-317.
15. Vassiliadis S, Ranella A, Papadimitriou L, Makrygiannakis A, Athanassakis I: Serum levels of pro- and anti-inflammatory cytokines in non-pregnant women, during pregnancy, labour and abortion. Mediat Inflamm 1998; 7:69-72.
16. Stallmach T, Hebisch G, Joller-Jemelka HI, Orban P, Schwaller J, Engelmann M: Cytokine production and visualized effects in the feto-maternal unit. Quantitative and topographic data on cytokines during intrauterine disease. Lab Invest 1995; 73:384-395.
17. Raghupathy R: ThI-type immunity is incompatible with successful pregnancy. Immunol Today 1997; 18:478-482.
18. Gratakos E, Filella X, Palacio M, Cararach V, Alonso PL, Fortuny A: Interleukin-4, interleukin-10 and granulocyte-macrophage colony stimulating factor in second-trimester serum from women with preeclampsia. Obstet Gynecol 1998; 92:849-853.
19. Kanzaki H, Crainie M, Lin H, Yui J, Guilbert LJ, Mori T, Wegmann TG: The in situ expression of granulocyte-macrophage colony stimulating factor (GM-CSF) mRNA at the maternal-fetal interface. Growth Factors 1991; 5:69-74.
20. Jokhi PP, King A, Loke YW: Production of granulocyte-macrophage colony-stimulating factor by human trophoblast cells and by decidual large granular lymphocytes. Hum Reprod 1994; 9:1660-1669.
21. Kekow J, Reinhold D, Pap T, Ansorge S: Intravenous immunoglobulins and transforming growth factor. Lancet 1998; 351:184-185.
22. Chegini N, Tang XM, Dou Q: The expression, activity and regulation of granulocyte macrophage-colony stimulating factor in human endometrial epithelial and stromal cells. Mol Hum Reprod 1999; 5:459-466.
23. Savion S, Zeldich E, Orenstein H, Shepshelovich J, Torchinsky A, Carp H, Toder V, Fein A: Cytokine expression in the uterus of mice with pregnancy loss: Effect of maternal immunopotentiation with GM-CSF. Reproduction 2002; 123:399-409.
24. Gordon MY, Riley GP, Watt SM, Greaves MF: Compartimentalization of a haemopoietic growth factor (GM-CSF) by glycosaminoglycans in the bone marrow microenvironment. Nature 1987; 326:403-405.
25. Jerzak M, Rechberger T, Gorski A: Intravenous immunoglobulin therapy influences T cell adhesion to extracellular matrix in women with a history of recurrent spontaneous abortion. Am J Reprod Immunol 2000; 44:336-441.
26. Revoltella RP, Laricchia Robbio L, Liberati AM, Reato G, Foa R, Funaro A, Vinante F, Pizzolo G: Antibodies binding granulocyte-macrophage colony stimulating factor produced by cord blood-derived B cell lines immortalized by Epstein-Barr virus in vitro. Cell Immunol 2000; 204:114-127.
27. Fishman P, Bakimer R, Blank M, Sredni D, Djaldetti M, Shoenfeld Y: The putative role of cytokines in the induction of primary anti-phospholipid syndrome in mice. Clin Exp Immunol 1992; 90:266-270.
28. Fishman P, Falach-Vaknine E, Zigelman R, Bakimer R, Sredni B, Djaldetti M, Shoenfeld Y: Prevention of fetal loss in experimental antiphospholipid syndrome by in vivo administration of recombinant interleukin-3. J Clin Invest 1993; 91:1834-1837.
29. Blank M, George J, Fishman P, Levy Y, Toder V, Savion S, Barak V, Koike T, Shoenfeld Y: Ciprofloxacin immunomodulation of experimental antiphospholipid syndrome associated with elevation of interleukin-3 and granulocyte-macrophage colony-stimulating factor expression. Arthritis Rheum 1998; 41:224-232.
30. Valensise H, Vaquero E, De Carolis C, Stipa E, Perricone R, Arduini D, Romanini C: Normal fetal growth in women with antiphospholipid syndrome treated with IVIg. Prenat Diagn 1995; 15:509-517.